What changed for Retinal Vein Occlusion and Diabetic Macular Oedema
A plain English summary of what recently moved in the public data Voxsanity tracks for Retinal Vein Occlusion and Diabetic Macular Oedema. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials on record 882 to 880 (-2)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Retinal Vein Occlusion and Diabetic Macular Oedema in July 2026. Voxsanity tracks 4 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 162 trials tracked for Retinal Vein Occlusion and Diabetic Macular Oedema that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04692688 · results posted 8 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04692688) enrolled 103 people with diabetic retinopathy — a complication of diabetes that affects the eyes. Participants were split into two groups: 51 people received a treatment called APX3330, and 52 received a placebo (a dummy pill with no active ingredient). The trial was measuring changes in the severity of their diabetic retinopathy using a standard rating scale called the DRSS (Diabetic Retinopathy Severity Score), which runs from 10 to 90, where a higher number means a worse result. A total of 91 people completed...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05217680 · results posted 26 May 2026
According to the results reported on ClinicalTrials.gov, this trial compared two eye injection treatments — an investigational medicine called PRO-169 and an already-approved medicine called Lucentis® (ranibizumab) — in people with a retinal eye condition. A total of 509 people were enrolled (255 in the PRO-169 group and 254 in the Lucentis® group), though the number who completed the full 12-month trial was 186 and 189 respectively. The main thing the trial was measuring was how much participants' best corrected visual acuity (that is, the sharpest vision possible with glasses or lenses, test...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05151731 · results posted 11 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05151731) enrolled 394 participants across four groups. Three groups received different doses or schedules of an investigational treatment called vamikibart (either 0.25 mg every 8 weeks, 1 mg every 8 weeks, or 1 mg every 4 weeks), while a fourth group received an existing treatment called ranibizumab (0.5 mg every 4 weeks) for comparison. The trial was measuring changes in vision sharpness over time, as well as tracking unwanted medical events (called adverse events) that occurred during the study. Participants were split...
-
NCT05850520 · results posted 18 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 892 people in total across three groups, all receiving a medicine called aflibercept as eye injections for an eye condition affecting vision. The three groups differed in the dose and timing of their injections: one group (301 people) received a lower dose every 4 weeks ("2q4"), a second group (293 people) received a higher dose on an every-8-week schedule with up to 3 loading injections ("8q8/3"), and a third group (298 people) received the same higher dose on a similar schedule but with up to 5 loading injections ("...
-
NCT05151744 · results posted 16 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 187 people in total — 93 in the group receiving a combination of vamikibart and ranibizumab (Arm A), and 94 receiving ranibizumab alone (Arm B). Participants were split into two sub-groups: those who had never previously been treated for their eye condition (124 people) and those who had received prior treatment (63 people). The trial's main focus was measuring changes in vision — specifically "best corrected visual acuity" (BCVA), which is simply how well a person can see on a standard eye chart — over roughly a year...
-
NCT05301751 · results posted 15 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 25 people in total, spread across four groups (called cohorts): 3 people in Cohort 1, 6 in Cohort 2, 8 in Cohort 3, and 8 in Cohort 4. Almost all participants completed the study — one person in Cohort 3 did not finish. The trial was measuring changes in two things related to eye health: how well participants could read letters on a standardised eye chart (known as "best corrected visual acuity"), and changes in the thickness of a specific layer at the back of the eye (called "central subfield thickness"), measured us...
-
NCT05511038 · results posted 4 September 2025
According to the results reported on ClinicalTrials.gov, a total of 121 people took part in this trial — 105 in a group who had not previously received treatment for their eye condition (called "Naïve") and 16 who had already had some prior treatment ("Pre-Treated"). The trial was looking at a treatment for a retinal eye condition and measured two main things: any unwanted medical events (called adverse events) that occurred during treatment, and how participants' vision and eye health changed over 52 weeks (about one year). Each participant had one eye enrolled in the study. The reported dat...
-
NCT05697809 · results posted 3 September 2025
According to the results reported on ClinicalTrials.gov, this trial (called OXEYE) enrolled a very small number of participants — 1 person in the mid-dose group and 2 people in the high-dose group of a treatment called OXU-001, which was delivered using a special device called Oxulumis into the space at the back of the eye. Three other groups (a second mid-dose group, a second high-dose group, and a comparison group receiving an existing treatment called Ozurdex®) had zero participants enrolled. All participants who started the trial completed it. The trial was primarily measuring any unwanted...
-
NCT06011798 · results posted 5 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06011798) enrolled 52 people in total — 26 in a control group who received a standard anti-VEGF eye injection treatment, and 26 in a group who received a drug called foselutoclax. The trial was primarily measuring changes in vision, specifically how many letters participants could read on a standardised eye chart (called an ETDRS chart) after treatment, compared to when they started. Most participants finished the study — 23 in the control group and 24 in the foselutoclax group. The reported data shows that, for the main...
-
NCT06181227 · results posted 14 July 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called AVD-104, given at two different dose levels — a low dose and a high dose. A total of 21 people took part: 10 in the low-dose group and 11 in the high-dose group. The trial was measuring whether any serious eye-related safety events occurred, as well as tracking two things in the eye over time: the thickness of a central layer at the back of the eye (called central subfield thickness, measured in microns — a very small unit of length), and vision sharpness (measured using a standard eye chart scorin...
-
NCT04418427 · results posted 10 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04418427) looked at a condition called diabetic macular oedema (DME) — a build-up of fluid in the central part of the retina that can affect vision in people with diabetes. A total of 36 people were enrolled across three groups: 13 received a higher dose of a gene therapy called ADVM-022, 13 received a lower dose of ADVM-022, and 10 received the comparison treatment, aflibercept injections combined with a sham (dummy) procedure. The main thing the trial was measuring was how long it took for signs of DME to get noticeably...
-
NCT04565756 · results posted 9 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04565756) enrolled 48 people in total across six groups. Participants had diabetic macular oedema (a build-up of fluid in the back of the eye related to diabetes). The trial tested an eye drop medicine called EXN407 at three different strengths (0.5 mg/mL, 1.0 mg/mL, and 1.5 mg/mL) compared with a placebo (inactive) eye drop. The main thing the trial set out to measure was how many participants experienced eye-related unwanted events — called "treatment-emergent adverse events" — after using the drops. The trial also track...
-
NCT05832996 · results posted 4 March 2025
According to the results reported on ClinicalTrials.gov, this trial looked at whether the temperature of artificial tear eye drops — either cooled or at room temperature — made a difference to the level of eye discomfort people felt after receiving an injection into the eye (known as an intravitreal injection). A total of 124 participants were enrolled across two groups: 56 people in the cooled artificial tear group and 68 people in the room temperature artificial tear group. Of those, 48 and 61 participants respectively completed the trial, meaning 8 and 7 people did not finish in each group....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04707625 · results posted 24 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04707625) involved 17 participants who all received a treatment called aflibercept, which was given as an injection into the eye. The trial was looking at changes in swelling at the back of the eye (called macular oedema), the volume of that swelling, levels of a particular protein in the eye linked to fluid build-up (called VEGF), and vision. It is worth noting that while 17 participants started the trial, the data shows that none were recorded as having formally "completed" it — all 17 were listed under "not completed,"...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03519581 · results posted 17 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03519581) compared two groups of people with a retinal condition: one group received micropulse laser treatment and the other received a sham (pretend) treatment. A total of 27 people were enrolled — 16 in the laser group and 11 in the sham group. However, only 4 people (2 in each group) completed the study, with 23 participants not finishing. The main thing the trial was measuring was how many participants experienced a meaningful drop in vision — specifically, vision falling to a level of 20/40 or worse based on a standa...
-
NCT05269966 · results posted 10 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 105 people who received the eye injection treatment brolucizumab over 56 weeks (about one year). Of those, 95 people completed the study and 10 did not finish. The trial was primarily measuring what unwanted medical events (called adverse events) occurred that were thought to be related to the treatment. It also tracked changes in participants' vision using a standard eye chart reading test, where a higher score means better vision. The reported data shows that, for the primary focus of the study — tracking treatment...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05512962 · results posted 20 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05512962) enrolled 25 people in total — 13 in a lower-dose group (2.4 mg) and 12 in a higher-dose group (4.0 mg). The trial was testing two different doses of a steroid medicine called triamcinolone acetonide, delivered into the back of the eye using a small device called the Oxulumis® microcatheter. The main things being measured were how often participants experienced unwanted events (side effects) related to the treatment or the device. The trial also tracked eye pressure, the thickness of a part of the retina called th...
-
NCT04292912 · results posted 8 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04292912) involved a single group of 16 participants who all received the investigational treatment GSK2798745. Nine participants completed the study, while seven did not finish. The trial was measuring a range of safety-related indicators over 28 days, including eye health, vision, body weight, body temperature, blood pressure, and pulse rate. The reported data shows the following numbers for changes between the start of the study and Day 28: vision (measured using a standard letter-reading chart, where higher scores mea...
-
NCT04264819 · results posted 7 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04264819) enrolled 295 people with a condition called neovascular age-related macular degeneration (nAMD) — a form of age-related macular degeneration where abnormal blood vessels grow in the eye and can affect vision. All participants received the study drug, brolucizumab (also called RTH258). The trial tracked whether signs of active disease could still be detected in participants' eyes at certain points in time, and also measured changes in the thickness of the retina (the light-sensitive layer at the back of the eye) u...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04432831 · results posted 30 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04432831) enrolled 1,474 people across three groups, all of whom had previously been receiving treatment for a retinal eye condition. One group (493 people) had previously been on faricimab given every 8 weeks, another (506 people) had previously been on faricimab on a flexible "treat-and-extend" schedule, and a third (475 people) had previously been on a different medicine called aflibercept every 8 weeks. All three groups then continued or switched to faricimab on a flexible dosing schedule. The trial's primary focus was...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04058067 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04058067) enrolled 263 people — 132 in the brolucizumab 6 mg group and 131 in the aflibercept 2 mg group. Of those, 120 in each group completed the study. The trial was measuring changes in best-corrected visual acuity (BCVA) — that is, the sharpest vision a person can achieve with glasses or lenses — in the study eye over 52 weeks (roughly one year). Vision was scored on a standardised chart (called an ETDRS chart), where scores range from 0 to 100 and a higher score means better visual function. The reported data shows...
-
NCT04611152 · results posted 22 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04611152) enrolled 460 people in total — 230 in each group. One group received an investigational treatment called KSI-301, and the other received aflibercept, an existing eye injection used for diabetic macular oedema (a condition where fluid builds up at the back of the eye, affecting vision). The trial's main goal was to measure any change in vision — specifically, how many letters participants could read on a standardised eye chart — from the start of the trial to around weeks 60 and 64. By the end of the study, 204 pe...
-
NCT04603937 · results posted 22 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04603937) enrolled 457 people in total — 229 received a treatment called KSI-301 and 228 received a comparator treatment called aflibercept. Both treatments are given as injections into the eye and were being studied in people with a condition affecting the retina (the light-sensitive layer at the back of the eye). The trial ran for over a year, and the main thing being measured was whether participants' vision changed — specifically, their best-corrected visual acuity (that is, the sharpest vision possible, even with glas...
-
NCT04805541 · results posted 15 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 900 people in total, with 865 completing the study and 35 not completing it. The trial was testing an AI-based eye screening tool called EyeCheckup, which analyses photos of the back of the eye to detect signs of diabetic retinopathy (a diabetes-related eye condition). The tool was tested using three different camera brands — Optomed, Canon, and Topcon — to see how accurately it could identify two levels of concern: signs beyond mild diabetic retinopathy, and vision-threatening diabetic retinopathy. The reported data...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04592419 · results posted 6 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04592419) enrolled 284 participants in each of two groups — one group received a medicine called KSI-301, and the other received a medicine called aflibercept. Both medicines were being tested as treatments for retinal vein occlusion (RVO), a condition where a vein in the back of the eye becomes blocked. The trial measured changes in participants' best-corrected visual acuity — that is, the sharpest vision a person can achieve, even with glasses or contact lenses — using a standardised letter-reading chart (ETDRS), where a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04857996 · results posted 16 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04857996) involved 65 people in total — 33 in a "sham control" group (who received a dummy procedure) and 32 who received a single injection of UBX1325, a drug being studied for eye disease. The trial was measuring how the body and eyes responded to the injection, and also tracking changes in vision over time. Of those who started, 26 people in the sham group and 24 in the UBX1325 group completed the study. The reported data shows that for whole-body (systemic) side effects, 4 participants in the sham group and 5 in the U...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04697758 · results posted 22 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04697758) enrolled a small number of participants across three planned dose groups — a low dose group, a mid dose group, and a high dose group. Three people started and completed the low dose group, three people started and completed the mid dose group, and no participants were enrolled in the high dose group. The trial was measuring safety by looking at how many participants experienced unwanted health events (called adverse events), both in the eye being treated and in the body more generally. The reported data shows th...
-
NCT05182580 · results posted 6 February 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05182580) involved 993 participants in total — 494 in the intervention group (where an autonomous artificial intelligence system was used to assess patients with diabetes) and 499 in the control group (who received usual care). All participants completed the study with no drop-outs recorded. The trial was measuring how many patient care appointments could be completed per hour of a retina specialist's clinic time, comparing the two approaches. The reported data shows that in the intervention group, the AI system completed...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04740905 · results posted 18 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04740905) enrolled 553 people in total — 276 in one group (Arm A) and 277 in the other (Arm B). The trial was testing two eye injection treatments, faricimab and aflibercept, in people with a condition affecting their vision. The study ran in two parts: the first 24 weeks (Part 1) compared the two treatments given every four weeks, and a second phase ran through to week 72. The main thing the trial was measuring was how much participants' vision changed from the start of the trial to week 24, using a standard eye chart tes...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04740931 · results posted 18 January 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04740931) enrolled 729 participants in total — 366 in Arm A (receiving faricimab every four weeks) and 363 in Arm B (receiving aflibercept every four weeks) during the first part of the study (up to 24 weeks). In the second part of the study (weeks 24 to 72), both groups switched to or continued faricimab on a personalised dosing schedule. The trial was primarily measuring changes in vision sharpness — specifically, how many letters participants could read on a standardised eye chart — compared to where they started at the...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 162 reported results for Retinal Vein Occlusion and Diabetic Macular Oedema
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a moderate amount of public research funding has been directed toward Retinal Vein Occlusion and Diabetic Macular Oedema, which suggests these conditions have attracted meaningful scientific attention at a global level. However, the direction of that funding has been falling year on year, meaning the financial commitment from public sources appears to be declining ra...
See the full Retinal Vein Occlusion and Diabetic Macular Oedema page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.